loading page

Effect of triple combination therapy with lopinavir-ritonavir, azithromycin and hydroxychloroquine on QT interval and arrhythmic risk in hospitalized COVID-19 patients.
  • +9
  • Vincenzo Russo,
  • Andreina Carbone,
  • Filiberto Fausto Mottola,
  • Rosa Mocerino,
  • Raffaele Verde,
  • Emilio Attena,
  • Nicoletta Verde,
  • Piepaolo Di Micco,
  • Luigi Nunziata,
  • Francesco Santelli,
  • Gerardo Nigro,
  • Sergio Severino
Vincenzo Russo
Second University of Naples - Monaldi Hospital
Author Profile
Andreina Carbone
University of Campania "Luigi Vanvitelli" – Monaldi Hospital, Naples, Italy.
Author Profile
Filiberto Fausto Mottola
Ospedale Monaldi
Author Profile
Rosa Mocerino
Cotugno Hospital, Naples, Italy
Author Profile
Raffaele Verde
Cotugno Hospital
Author Profile
Emilio Attena
San Giuliano Hospital
Author Profile
Nicoletta Verde
Ospedale Monaldi
Author Profile
Piepaolo Di Micco
Madonna del Buon Consiglio Fatebenefratelli di Napoli Hospital
Author Profile
Luigi Nunziata
Boscotrecase Hospital
Author Profile
Francesco Santelli
University of Naples Federico II
Author Profile
Gerardo Nigro
University of Campania Luigi Vanvitelli
Author Profile
Sergio Severino
Cotugno Hospital
Author Profile

Abstract

Introduction: no data are provided about the effect of triple combination therapy with Lopinavir/Ritonavir (LPN/RTN), hydroxychloroquine (HQ) and azithromycin (AZT) on corrected QT (QTc) interval and arrhythmic risk, in COVID-19 patients. This study aims to describe the incidence of extreme QTc interval prolongation among COVID-19 patients on this experimental treatment and to identify the clinical features associated with extreme QTc prolongation. Materials and methods: data of 87 COVID-19 patients, treated with triple combination including LPN/RTN, HQ and AZT, were analyzed. QT interval was obtained by the tangent method and corrected for heart rate using Bazett’s formula. Extreme QTc interval prolongation was considered an absolute QTc interval ≥ 500 ms or an increase in QTc intervals of 60 milliseconds or greater (ΔQTc ≥ 60 milliseconds) compared with baseline. Results: Hypertension (66.7%) and diabetes (25.3%) were the most prevalent cardiovascular comorbidities. 20 patients (23%) showed extreme QTc interval prolongation; No clinical, electrocardiographic or pharmacological characteristics have been associated to extreme QTc prolongation, except the history of ischemic stroke (P= 0,007). One torsade de pointes (TdP) in patient with QTc extreme prolongation (QTc: 560 ms) after 5 days of therapy was recorded. Conclusions: We observed a high incidence of extreme QTc interval prolongation among COVID-19 patients on triple combination therapy. The incidence of malignant arrhythmias seems to be low, a careful electrocardiographic monitoring would be advisable.